



# MANUFACTURING AND SUPPLY CHAIN

Through a global supply network, Pfizer ensures supply of quality products that potentially significantly improve patients' lives, and that these products are available whenever and wherever they are needed. Through consistent high standards for quality, compliance and supply reliability, and by delivering value without compromising quality or compliance, Pfizer's supply network provides fast, flexible solutions across the full manufacturing and supply chain spectrum and delivers safe, effective medicines around the world.



“We’re working on bringing Prevenar 13® to patients around the world, every day. Our Prevenar manufacturing network can be best described as a finely tuned ecosystem, where quality, compliance, technical capability and world-class facilities with highly skilled and dedicated colleagues come together to make that happen.”

– Enda Doyle  
Vice President, Pfizer Global Supply, Vaccines Product Portfolio Management

## FOOTPRINT AND CAPABILITIES GROW WITH HOSPIRA ACQUISITION

The Hospira acquisition enhances our ability to address global demand for specialized medicines, adding global talent and significant global manufacturing infrastructure — 11 biopharma manufacturing sites including two of the largest and most advanced sterile injectable manufacturing facilities in the world. The integration also adds two facilities for the manufacture of proprietary IV sets and infusion pumps to support the Infusion Systems business.

We are well-practiced in integrating acquired assets and bringing them to our global, uncompromising standards of quality and compliance. This is accomplished through continually improving our integration playbook, rapid alignment of operations, clear alignment of colleague reporting lines and sharing of best practices. Our global supply network reflects the successful aggregation of more than 30 merged companies over the last 15 years.



Pfizer’s facility at Vizag in India is one of the largest sterile injectable manufacturing units in the world.

### OUR CURRENT EXPANDED FOOTPRINT\*

	2014	2015
Markets	175+	175+
Internal Manufacturing Sites	55	64
Device Manufacturing Sites	0	2
Supply Partners	200+	200+
Logistics Centers	130	134
Major Product Groups	600+	850+

\*As of 2/9/2016. Does not reflect pending transactions.



## QUALITY

Our quality management systems and processes drive quality-focused behaviors and ensure decision making based on what is best for patient and consumer safety, product quality, and Pfizer’s reputation and business.

## PREVENAR® MANUFACTURING — GLOBAL NETWORK

Prevenar 13® (pneumococcal polysaccharide conjugate vaccine, 13-valent adsorbed) is one of the most technically complex vaccines to manufacture, and to optimize logistics and local supply, we produce it in many parts of the world. Our robust manufacturing process is applied globally, ensuring exceptional quality across all markets and patients. Consistently producing such a highly complex vaccine at high quality and getting it to patients relies on our manufacturing colleagues’ experience, technical skills, dedication and passion for making a difference in people’s lives.



**BILLION**

WE RECENTLY PRODUCED OUR BILLIONTH DOSE IN THE PREVNAR/ PREVNAR FRANCHISE.

**“We put tremendous focus on each dose, as what we do needs to be perfect every time. I am proud of the team’s commitment to changing lives and celebrate our work to manufacture the one billionth dose of Prevenar and Prevenar 13® this year.”**

— Enda Doyle  
Vice President, Pfizer Global Supply, Vaccines Product Portfolio Management

**ONE DOSE OF PREVNAR 13 FROM START TO FINISH TAKES THE WORK OF**

<b>1,700</b> EMPLOYEES	<b>678</b> QUALITY TESTS	<b>400</b> DIFFERENT RAW MATERIALS
<b>580</b> STEPS IN MANUFACTURING	<b>2.5</b> YEARS TO MANUFACTURE	



---

## SUPPLY CHAIN MANAGEMENT

---

In our global manufacturing, within our distribution network and in our work with external partners, we produce and distribute technically complex formulations, packaging and entire lines of medicines that meet exacting standards for quality and effectiveness. Our Highly Orchestrated Supply Network (HOSuN) is designed to align inventory and supply chain planning, transportation management, temperature control management, logistics and logistics security, environmental health and safety, dangerous goods compliance, global trade compliance and trade management. It also supports business continuity and proactive issue identification and resolution.

Pfizer is an industry-recognized leader in supply chain security. Our dedicated security program encompasses every part of the manufacturing and delivery process, starting with the procurement of raw materials and continuing through to the delivery of product to our customers. Our serialization program is designed for additional control and authentication across the supply chain while our trade programs manage partnerships with our distributors to help protect our products and ensure integrity.

Pfizer is committed to responsible supply chain management and holds all manufacturing and supply partners to high standards of excellence. We partner with external suppliers who are committed to operating their businesses in a responsible and ethical manner, respecting the rights of the individuals they employ and helping to protect the environment. Pfizer strongly encourages its supply partners to support our Supplier Conduct Principles or adopt their own codes with expectations similar to ours.

---

## ENVIRONMENTAL HEALTH AND SAFETY (EHS) IN THE SUPPLY CHAIN

---

Pfizer operates within a framework of principles aligned with ethical, social and environmental responsibilities to help ensure the sustainability of our business and the communities in which we operate. To that end, our Environmental Health and Safety (EHS) team and our plant site colleagues oversee efforts and perform risk-based reviews to help ensure that our chemical and biological product suppliers effectively manage risk.

### Directly Supporting Our Suppliers

Pfizer has an established EHS supplier review program to ensure our suppliers' EHS performance meets or exceeds our expectations. This program includes supplier assessments and, where necessary, capacity building to supplement EHS understanding and performance. Pfizer has a strong history of providing EHS support to help our suppliers enhance their performance.

In 2014, Pfizer evaluated this program and, as a result, in 2015, we modified the program to increase our focus on elevated risk suppliers and performed in-depth reviews in key risk areas such as process safety and environmental management. In 2016, we will increase the number of reviews we perform of suppliers in locations such as India and China, where the country EHS infrastructure continues to develop.

The supplier review program has enabled a balanced approach that considers business, product, reputational and process risks, and because of the enhancements, introduced better focus on mitigating key risks. Preliminary outcomes indicate that the focused assessments are driving further continual improvement at elevated risk suppliers.



**“I am working with suppliers in Asia to ensure they have sound EHS practices, consistent with Pfizer expectations, in place. I do this by leading on-site supplier reviews that help lower the reputational and business continuity risk to Pfizer. More importantly, I do this to help our suppliers build their own capabilities in EHS management.”**

– YS Tan  
Director, EHS Asia

## **Taking a Leadership Role in the Pharmaceutical Supply Chain Initiative**

The Pharmaceutical Supply Chain Initiative (PSCI), an industry-wide trade association, creates a common platform to drive continuous improvement across the supply chain to improve labor, ethics, environmental, and health and safety practices. Pfizer is an active PSCI member with a Pfizer colleague serving as Vice Chair of the Board in 2015 and Chair of the Board in 2016. We played a leadership role on the committee that was instrumental in developing the agenda and conducting the PSCI India conference held in Mumbai, India, where more than 150 supplier representatives took part in learning opportunities.

In 2015, a new audit sharing model and commitment was agreed to by all PSCI members. The pace of shared audits is increasing, with a total of 50 new audits anticipated by the middle of 2016. Upcoming PSCI efforts include holding a webinar on pharmaceuticals in the environment; analyzing labor practices requirements (e.g., the U.K. Modern Slavery Act) and developing guidance material; developing common “response templates” for inquiries from third party organizations; and, developing reporting criteria for supplier sustainability performance.

The work that Pfizer is doing with suppliers, either directly or through PSCI, helps us make the right decisions in terms of selecting new suppliers and improving EHS performance at our existing suppliers.